In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.83 million on Dec 02 ’24. In the deal valued at $55.10 per share,15,000 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 181,540 shares worth roughly $7.35 million.
Then, Kulkarni Samarth sold 30,000 shares, generating $1,668,678 in total proceeds. Upon selling the shares at $55.62, the Chief Executive Officer now owns 196,540 shares.
Before that, KASINGER JAMES R. sold 1,089 shares. CRISPR Therapeutics AG shares valued at $50,399 were divested by the General Counsel and Secretary at a price of $46.28 per share. As a result of the transaction, KASINGER JAMES R. now holds 62,597 shares, worth roughly $2.53 million.
H.C. Wainwright initiated its CRISPR Therapeutics AG [CRSP] rating to a Buy in a research note published on February 03, 2025; the price target was $65. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early August has reiterated a ‘”a Buy”‘ rating for it. Rodman & Renshaw began covering CRSP with “Buy” recommendation on August 02, 2024.
Price Performance Review of CRSP
On Tuesday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 1.23% to $40.49. Over the last five days, the stock has lost -3.16%. CRISPR Therapeutics AG shares have risen nearly 2.87% since the year began. Nevertheless, the stocks have fallen -37.39% over the past one year. While a 52-week high of $91.10 was reached on 01/22/25, a 52-week low of $36.52 was recorded on 01/13/25. SMA at 50 days reached $43.94, while 200 days put it at $50.04.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 39.79, which if violated will result in even more drops to 39.09. On the upside, there is a resistance level at 41.15. A further resistance level may holdings at 41.81. The Relative Strength Index (RSI) on the 14-day chart is 44.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.89, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.74%. Stochastics %K at 33.91% indicates the stock is a holding.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-01-15, growing by 2.19 million shares to a total of 20.31 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 18.12 million shares. There was a rise of 10.81%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating .
